Incyte Corporation (INCY) Shares Bought by Toronto Dominion Bank
Toronto Dominion Bank boosted its holdings in Incyte Corporation (NASDAQ:INCY) by 12.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 64,904 shares of the biopharmaceutical company’s stock after purchasing an additional 7,320 shares during the period. Toronto Dominion Bank’s holdings in Incyte Corporation were worth $7,576,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of INCY. Cornerstone Advisors Inc. lifted its holdings in Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after buying an additional 145 shares during the period. Tower Research Capital LLC TRC grew its holdings in shares of Incyte Corporation by 13.8% in the second quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 108 shares during the period. Seven Eight Capital LP bought a new stake in shares of Incyte Corporation in the second quarter worth $129,000. IFP Advisors Inc lifted its position in Incyte Corporation by 9.9% during the second quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 103 shares in the last quarter. Finally, Sun Life Financial INC lifted its position in shares of Incyte Corporation by 9,069.2% in the second quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 1,179 shares in the last quarter. 89.53% of the stock is currently owned by institutional investors and hedge funds.
INCY has been the topic of a number of recent research reports. BMO Capital Markets restated a “buy” rating and issued a $172.00 price objective on shares of Incyte Corporation in a research note on Friday, July 21st. Jefferies Group LLC reaffirmed a “buy” rating and set a $148.00 target price on shares of Incyte Corporation in a research report on Thursday, July 27th. J P Morgan Chase & Co set a $149.00 target price on shares of Incyte Corporation and gave the company a “buy” rating in a research note on Tuesday, August 1st. Barclays PLC reissued an “overweight” rating and issued a $165.00 price objective (down previously from $180.00) on shares of Incyte Corporation in a report on Wednesday, August 2nd. Finally, BidaskClub cut Incyte Corporation from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Seven investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $144.98.
Shares of Incyte Corporation (INCY) opened at $106.83 on Friday. Incyte Corporation has a 1-year low of $98.49 and a 1-year high of $153.15. The company has a quick ratio of 4.81, a current ratio of 4.82 and a debt-to-equity ratio of 0.01.
Incyte Corporation (NASDAQ:INCY) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm’s revenue for the quarter was up 41.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 EPS. equities research analysts predict that Incyte Corporation will post -1.3 earnings per share for the current fiscal year.
In other Incyte Corporation news, President Herve Hoppenot sold 70,502 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $119.45, for a total value of $8,421,463.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David W. Gryska sold 3,915 shares of the business’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $105.63, for a total transaction of $413,541.45. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 102,062 shares of company stock valued at $12,652,893. 17.70% of the stock is owned by company insiders.
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.